German funds select Imraldi due to price
Deep initial discounts of up to 40% versus AbbVie’s Humira (adalimumab) original have won Biogen’s Imraldi alternative a nationwide supply contract with Germany’s GWQ group of health insurance funds.
Deep initial discounts of up to 40% versus AbbVie’s Humira (adalimumab) original have won Biogen’s Imraldi alternative a nationwide supply contract with Germany’s GWQ group of health insurance funds.